Polaryx Therapeutics, Inc. PLYX
Set alert
As of Nov 3, 2:22 PM ET
- YTD
- -94.89%
- 1 year
- -94.89%
- Open
- 1.73
- Prev close
- 1.75
- Mkt cap
- 82.61M
- Vol
- 15.02K
- Avg vol
- 54.96K
- EPS
- -0.14
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.69
- High
- 1.78
News
1 month ago benzinga.com
Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Webuy Global shares jumped 15% premarket after H1 revenue nearly doubled to $14.31M and net loss narrowed; Game Your Game led gainers, Masonglory fell.
2 months ago globenewswire.com
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles
2 months ago globenewswire.com
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four…
2 months ago benzinga.com
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Wall Street analysts changed outlook on top names. Check analyst ratings page for all changes. See what analysts think of MTN stock.
-
2 months ago benzinga.com
Raymond James Initiates Coverage On Polaryx Therapeutics with Strong Buy Rating, Announces Price Target of $6
Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Strong Buy rating and announces Price Target of $6.
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
-
3 months ago benzinga.com
LUCID CAPITAL MARKETS Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.
-
3 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals…
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
5 months ago benzinga.com
Why Polaryx Therapeutics Stock Is Surging On Thursday?
Polaryx Therapeutics (NASDAQ: PLYX) stock climbs on Thursday following a $10M private placement to launch its Phase 2 SOTERIA trial for rare lysosomal storage disorders.
5 months ago globenewswire.com
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying…
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
5 months ago globenewswire.com
Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards
Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner Company selected as Best Pediatric Lysosomal…
6 months ago globenewswire.com
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric…
-
6 months ago benzinga.com
Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of JNCL/CLN3 Disease, Krabbe Disease, And Sandhoff Disease
Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug…
6 months ago globenewswire.com
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs,…
6 months ago globenewswire.com
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Company selected as a Diamond honoree for Excellence in Pediatric Care Company selected as a Diamond honoree for Excellence in Pediatric Care
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
7 months ago globenewswire.com
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
7 months ago benzinga.com
Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis
Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx…
7 months ago globenewswire.com
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric lysosomal…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
7 months ago globenewswire.com
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric…
-
8 months ago benzinga.com
Maxim Group Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $10
Maxim Group analyst Jason McCarthy initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $10.
8 months ago globenewswire.com
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
8 months ago feeds.benzinga.com
What's Going On With Polaryx Therapeutics Stock Wednesday?
Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement.
8 months ago benzinga.com
What's Going On With Polaryx Therapeutics Stock Wednesday?
Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement.
8 months ago benzinga.com
Dow Gains 100 Points; Analog Devices Posts Upbeat Q1 Earnings
Dow Gains 100 Points; Analog Devices Posts Upbeat Q1 Earnings
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
8 months ago benzinga.com
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans
Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial to evaluate lead candidate for lysosomal storage disorders.
8 months ago globenewswire.com
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
8 months ago globenewswire.com
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal…
8 months ago benzinga.com
Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings
Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings
8 months ago benzinga.com
Strategy, Bitmine Immersion Technologies And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 100 points on Monday.
8 months ago benzinga.com
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
9 months ago globenewswire.com
Polaryx Therapeutics Welcomes New Members of the Board of Directors
PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of…
9 months ago globenewswire.com
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug…
9 months ago benzinga.com
Why Teradyne Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
Why Teradyne Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
9 months ago globenewswire.com
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization…